CD19 and diffuse large B-cell lymphoma: At present, two CD19-targeted CAR-T cell therapies are FDA-approved for clinical use: tissuelecleucel for acute lymphocytic leukemia and diffuse large B cell lymphoma and axicabtagene ciloleucel for diffuse large B cell lymphoma [111, 112].